TY - JOUR
T1 - Alpidem in the treatment of panic disorder
AU - Schneier, Franklin R.
AU - Carrasco, Jose L.
AU - Hollander, Eric
AU - Campeas, Raphael
AU - Fallon, Brian
AU - Saoud, Jihad B.
AU - Feerick, John
AU - Liebowitz, Michael R.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1993/4
Y1 - 1993/4
N2 - Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.
AB - Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.
UR - http://www.scopus.com/inward/record.url?scp=0027450754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027450754&partnerID=8YFLogxK
U2 - 10.1097/00004714-199304000-00011
DO - 10.1097/00004714-199304000-00011
M3 - Article
C2 - 8096527
AN - SCOPUS:0027450754
SN - 0271-0749
VL - 13
SP - 150
EP - 153
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 2
ER -